Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The role of Palmitoylation ERASERs in cancer metastasis

Project description

Researchers target lethal cancer spread

Metastasis, the silent assassin in cancer, claims countless lives annually. Unfortunately, it has long eluded effective treatment. Recent breakthroughs reveal palmitate, a fatty acid, as a key player in fuelling metastasis. In this context, the ERC-funded PalmERASERs project will help decode the mystery behind palmitate’s unique pro-metastatic impact. The discovery of palmitoylation, a modification crucial for metastasising breast cancer cells, has sparked intrigue. Researchers hypothesise that palmitoylation ‘erasers’ are pivotal in sustaining pro-metastatic effects. The project aims to define erasers’ influence on pro-metastatic signalling, explore their regulation and assess their activity under diverse conditions. PalmERASERs holds promise as a proof of concept for palmitoylation-based therapies, potentially revolutionising metastasis prevention and treatment.

Objective

Metastasis is the major cause of death in patients with cancer. A better understanding of the mechanisms driving metastasis is critical to develop more effective anti-cancer treatments. The fatty acid palmitate has been recently identified as fuel for metastasis-promoting pathways. However, why palmitate has such a unique pro-metastatic effect compared to other fatty acids with similar metabolic fates remains elusive. Strikingly, I discovered that palmitoylation, a reversible post-translational protein modification driven solely by palmitate, is essential for metastasizing breast-cancer cells. Unexpectedly, I found that palmitoylation ‘erasers’, enzymes that remove the modification, are essential to sustain pro-metastatic effects of palmitate during metastatic colonization. Therefore, I hypothesize that, in palmitate-rich conditions (e.g under high-fat diet), palmitoylation anchor oncogenic proteins to membranes to get activated (functioning as a priming event), while erasers act as a rate-limiting release step, allowing primed proteins to engage in pro-metastatic signaling. I will investigate how the dynamics of palmitoylation promote metastasis by focusing on the erasers, whose role in metastasis remains largely unexplored. Specifically, I will: 1) define how erasers influence pro-metastatic signaling events in metastasizing cells; 2) investigate how erasers activity is regulated in metastasizing cells; and 3) assess how organ microenvironments and palmitate-rich diet condition eraser activity. I will address this by integrating multi-omics, molecular biology and mass spectrometry techniques with clinically relevant in vivo metastasis models. PalmERASERs will serve as a proof of concept for palmitoylation-based therapies with the goal of preventing or treating metastases. By focusing on the influence of diet, I will also enhance clinical translation of these findings by defining which patients will respond most effectively to palmitoylation-based therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-STG

See all projects funded under this call

Host institution

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 1 495 519,00
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
€ 1 495 519,00

Beneficiaries (1)